Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362733226> ?p ?o ?g. }
- W4362733226 endingPage "1073" @default.
- W4362733226 startingPage "1073" @default.
- W4362733226 abstract "Type II endometrial cancer (EC) is responsible for most endometrial cancer-related deaths due to its aggressive nature, late-stage detection, and high tolerance to standard therapies. Thus, novel treatment strategies for type II EC are imperative. For patients with mismatch repair-deficient (dMMR) tumors, immunotherapy with immune checkpoint inhibitors represents a promising therapeutic strategy. However, the prevalence of dMMR tumors in type II EC patients remains unclear. In this study, using immunohistochemistry, we evaluated the expression of mismatch repair (MMR) proteins, tumor-infiltrating lymphocytes (CD8+), and immune checkpoint molecules (PD-L1) in 60 patients with type II EC (16, 5, 17, and 22 were endometrioid G3, serous, de-differentiated, and carcinosarcoma cases, respectively) to investigate the therapeutic effect of immune checkpoint inhibitors. Approximately 24 cases (40%) had a loss of MMR protein expression. The positivity rate of CD8+ (p = 0.0072) and PD-L1 (p = 0.0061) expression was significantly associated with the dMMR group. These results suggest immune checkpoint inhibitors (anti-PD-L1/PD-1 antibodies) could effectively treat type II EC with dMMR. The presence of dMMR might be a biomarker for a positive response to PD-1/PD-L1 immunotherapy in type II EC." @default.
- W4362733226 created "2023-04-10" @default.
- W4362733226 creator A5009348197 @default.
- W4362733226 creator A5010897098 @default.
- W4362733226 creator A5011728066 @default.
- W4362733226 creator A5040402582 @default.
- W4362733226 creator A5057005039 @default.
- W4362733226 creator A5062197267 @default.
- W4362733226 creator A5070007977 @default.
- W4362733226 creator A5072556060 @default.
- W4362733226 creator A5074031156 @default.
- W4362733226 creator A5082807098 @default.
- W4362733226 creator A5083132734 @default.
- W4362733226 date "2023-04-09" @default.
- W4362733226 modified "2023-09-26" @default.
- W4362733226 title "Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status" @default.
- W4362733226 cites W1971208896 @default.
- W4362733226 cites W1976061263 @default.
- W4362733226 cites W1982488143 @default.
- W4362733226 cites W1994381471 @default.
- W4362733226 cites W1997025193 @default.
- W4362733226 cites W2012331065 @default.
- W4362733226 cites W2022936386 @default.
- W4362733226 cites W2028588553 @default.
- W4362733226 cites W2031222466 @default.
- W4362733226 cites W2041440766 @default.
- W4362733226 cites W2044869180 @default.
- W4362733226 cites W2049553585 @default.
- W4362733226 cites W2057893793 @default.
- W4362733226 cites W2065949107 @default.
- W4362733226 cites W2072891853 @default.
- W4362733226 cites W2079085536 @default.
- W4362733226 cites W2085158519 @default.
- W4362733226 cites W2089711940 @default.
- W4362733226 cites W2097200850 @default.
- W4362733226 cites W2097995306 @default.
- W4362733226 cites W2104347254 @default.
- W4362733226 cites W2107484016 @default.
- W4362733226 cites W2109485845 @default.
- W4362733226 cites W2117692326 @default.
- W4362733226 cites W2123363005 @default.
- W4362733226 cites W2123636561 @default.
- W4362733226 cites W2124427232 @default.
- W4362733226 cites W2125207696 @default.
- W4362733226 cites W2125616358 @default.
- W4362733226 cites W2154546296 @default.
- W4362733226 cites W2155401964 @default.
- W4362733226 cites W2156353875 @default.
- W4362733226 cites W2160834915 @default.
- W4362733226 cites W2165992619 @default.
- W4362733226 cites W2198093519 @default.
- W4362733226 cites W2258945793 @default.
- W4362733226 cites W2294957859 @default.
- W4362733226 cites W2339890238 @default.
- W4362733226 cites W2345624235 @default.
- W4362733226 cites W2401280080 @default.
- W4362733226 cites W2408417528 @default.
- W4362733226 cites W2414977199 @default.
- W4362733226 cites W2468958716 @default.
- W4362733226 cites W2510686645 @default.
- W4362733226 cites W2527905628 @default.
- W4362733226 cites W2560367415 @default.
- W4362733226 cites W2572174216 @default.
- W4362733226 cites W2599354912 @default.
- W4362733226 cites W2604441970 @default.
- W4362733226 cites W2605542695 @default.
- W4362733226 cites W2760942750 @default.
- W4362733226 cites W2777880635 @default.
- W4362733226 cites W2779221466 @default.
- W4362733226 cites W2789201876 @default.
- W4362733226 cites W2885308388 @default.
- W4362733226 cites W2901757914 @default.
- W4362733226 cites W2917680953 @default.
- W4362733226 cites W2955584715 @default.
- W4362733226 cites W2966152432 @default.
- W4362733226 cites W2980768918 @default.
- W4362733226 cites W2984359187 @default.
- W4362733226 cites W3025735868 @default.
- W4362733226 cites W3114074286 @default.
- W4362733226 cites W3128646645 @default.
- W4362733226 cites W3165700588 @default.
- W4362733226 cites W4211047904 @default.
- W4362733226 cites W4211172416 @default.
- W4362733226 cites W4213121772 @default.
- W4362733226 cites W4226407945 @default.
- W4362733226 cites W4281683023 @default.
- W4362733226 cites W4281732693 @default.
- W4362733226 cites W4288039625 @default.
- W4362733226 cites W89134798 @default.
- W4362733226 doi "https://doi.org/10.3390/healthcare11081073" @default.
- W4362733226 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37107907" @default.
- W4362733226 hasPublicationYear "2023" @default.
- W4362733226 type Work @default.
- W4362733226 citedByCount "0" @default.
- W4362733226 crossrefType "journal-article" @default.
- W4362733226 hasAuthorship W4362733226A5009348197 @default.
- W4362733226 hasAuthorship W4362733226A5010897098 @default.
- W4362733226 hasAuthorship W4362733226A5011728066 @default.